Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The Semaglutide + AOD-9604 stack combines the most powerful GLP-1 receptor agonist with a targeted fat-loss peptide for enhanced body composition results. Semaglutide suppresses appetite via central GLP-1 signaling, slows gastric emptying, and improves insulin sensitivity, while AOD-9604 (a modified fragment of human growth hormone amino acids 177-191) directly stimulates lipolysis without growth-promoting or diabetogenic effects. Together, these compounds address fat loss through complementary mechanisms: reduced caloric intake via appetite suppression and direct fat mobilization from adipose tissue.
Semaglutide activates GLP-1 receptors in the hypothalamus and gut, producing powerful appetite suppression, delayed gastric emptying, and improved insulin sensitivity. In clinical trials (STEP program), semaglutide produced 15-20% body weight reduction. It addresses the behavioral component of fat loss by dramatically reducing hunger and cravings.
AOD-9604 is the lipolytic fragment of HGH (amino acids 177-191) that directly stimulates fat breakdown in adipose tissue without affecting blood sugar or growth. While semaglutide reduces caloric intake from the top down, AOD-9604 attacks stored fat from the bottom up, specifically mobilizing stubborn adipose deposits that resist diet alone.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | Sema 0.25mg/wk (wk1-4), 0.5mg (wk5-8), 1mg (wk9+) | AOD 300mcg/day | AM fasted | 12-16 weeks |
| Aggressive | Sema titrate to 2.4mg/wk | AOD 500mcg/day | AM fasted | 16 weeks |
| Maintenance | Sema 0.5mg/wk | AOD 300mcg EOD | AM fasted | 8 weeks |
| Panel | Markers | Timing |
|---|---|---|
| Metabolic | Fasting glucose, HbA1c, fasting insulin | Baseline, Week 8, Week 16 |
| Lipid | Total cholesterol, LDL, HDL, triglycerides | Baseline, Week 8, Week 16 |
| Thyroid | TSH, free T4 | Baseline, Week 8 |
| Liver/Kidney | CMP, ALT, AST, lipase | Baseline, Week 8 |
Monitor metabolic markers closely. Semaglutide typically improves HbA1c and lipid profiles. Watch lipase for pancreatitis risk.
They should be administered as separate injections but can be given on the same day. AOD-9604 is best taken daily in the fasted AM window, while semaglutide is injected once weekly. Do not mix them in the same syringe.
With proper caloric deficit and exercise, subjects typically report 15-25 lbs over a 16-week protocol. Semaglutide alone showed 15-20% body weight reduction in trials. AOD-9604 may enhance fat mobilization from stubborn adipose depots.
Start semaglutide at 0.25mg weekly for the first 4 weeks to minimize GI side effects, then titrate to 0.5mg and eventually 1-2.4mg. AOD-9604 can be started at 300mcg daily from day one, injected subcutaneously in the morning on an empty stomach.
They should be administered as separate injections but can be given on the same day. AOD-9604 is best taken daily in the fasted AM window, while semaglutide is injected once weekly. Do not mix them in the same syringe.
With proper caloric deficit and exercise, subjects typically report 15-25 lbs over a 16-week protocol. Semaglutide alone showed 15-20% body weight reduction in trials. AOD-9604 may enhance fat mobilization from stubborn adipose depots.
Start semaglutide at 0.25mg weekly for the first 4 weeks to minimize GI side effects, then titrate to 0.5mg and eventually 1-2.4mg. AOD-9604 can be started at 300mcg daily from day one, injected subcutaneously in the morning on an empty stomach.
They should be administered as separate injections but can be given on the same day. AOD-9604 is best taken daily in the fasted AM window, while semaglutide is injected once weekly. Do not mix them in the same syringe.
With proper caloric deficit and exercise, subjects typically report 15-25 lbs over a 16-week protocol. Semaglutide alone showed 15-20% body weight reduction in trials. AOD-9604 may enhance fat mobilization from stubborn adipose depots.